questionText: To ask the Secretary of State for Health and Social Care, how many of the commercial arrangements made by NHS England with marketing authorisation holders between January 2020 and September 2025 involving indication-specific pricing were for indications f
answerText: Between January 2020 and September 2025, NHS England entered into 75 commercial arrangements involving indication-specific pricing. Of these, eight of the commercial agreements have involved indication-specific pricing for rare non-oncology conditions, an...
heading: Rare Diseases: Drugs